Allurion Technologies (NYSE:ALUR – Get Free Report) and Exagen (NASDAQ:XGN – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, institutional ownership, risk, dividends, analyst recommendations, earnings and valuation.
Valuation & Earnings
This table compares Allurion Technologies and Exagen”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Allurion Technologies | $17.21 million | 0.51 | -$7.20 million | ($2.03) | -0.29 |
| Exagen | $66.57 million | 1.69 | -$19.95 million | ($0.89) | -5.22 |
Analyst Recommendations
This is a breakdown of current ratings and target prices for Allurion Technologies and Exagen, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Allurion Technologies | 1 | 1 | 1 | 0 | 2.00 |
| Exagen | 1 | 0 | 8 | 1 | 2.90 |
Allurion Technologies currently has a consensus target price of $45.00, indicating a potential upside of 7,658.62%. Exagen has a consensus target price of $9.11, indicating a potential upside of 95.94%. Given Allurion Technologies’ higher possible upside, equities analysts plainly believe Allurion Technologies is more favorable than Exagen.
Profitability
This table compares Allurion Technologies and Exagen’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Allurion Technologies | -199.96% | N/A | -77.13% |
| Exagen | -29.49% | -94.37% | -28.96% |
Insider and Institutional Ownership
21.4% of Allurion Technologies shares are held by institutional investors. Comparatively, 75.3% of Exagen shares are held by institutional investors. 8.1% of Allurion Technologies shares are held by insiders. Comparatively, 10.4% of Exagen shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Risk and Volatility
Allurion Technologies has a beta of -0.13, meaning that its share price is 113% less volatile than the S&P 500. Comparatively, Exagen has a beta of 2.02, meaning that its share price is 102% more volatile than the S&P 500.
Summary
Exagen beats Allurion Technologies on 11 of the 15 factors compared between the two stocks.
About Allurion Technologies
Allurion Technologies Inc. focuses on ending obesity with a weight loss platform to treat people who are overweight. Its platform, the Allurion Program, features swallowable and procedure-less intragastric balloon for weight loss (the Allurion Balloon), as well as offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion Virtual Care Suite. Allurion Technologies Inc. is headquartered in Natick, Massachusetts.
About Exagen
Exagen Inc. develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus that measures activation of the complement system by quantifying the level of B-cell C4d and erythrocyte bound C4d in the patient's blood; and AVISE APS, which consists of a panel of autoantibody tests that aids in the diagnosis and management of APS. In addition, it provides AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody associated vasculitis; AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; and AVISE Anti-CarP test, which identifies RA patients with severe disease. Further, the company offers AVISE SLE Monitor, a biomarker blood test; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop novel patented biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.
Receive News & Ratings for Allurion Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allurion Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
